Zentiva Announces Sale from Advent to GTCR

Zentiva, a leading European generics pharmaceutical company, has been sold by Advent International to GTCR, two major global private equity firms announced today.

Advent acquired Zentiva from Sanofi in 2018 and spearheaded a significant transformation of the business. Through strategic investments in expanding Zentiva’s medicine portfolio and manufacturing capabilities—both organically and via targeted acquisitions—Advent helped Zentiva become a strong standalone company with a growing footprint across Europe.

GTCR, a private equity firm with deep expertise in healthcare and pharmaceuticals, plans to build on this foundation. Known for partnering with management teams to drive growth through innovation and acquisitions, GTCR is positioned to support Zentiva’s next chapter of expansion.

Steffen Saltofte, CEO of Zentiva, praised Advent’s role in the company’s development and expressed enthusiasm about continuing growth under GTCR’s ownership. “We are excited to build on this momentum to expand access to high-quality, affordable medicines across Europe,” Saltofte said.

Tom Allen, Managing Director at Advent, highlighted Zentiva’s strong performance under their stewardship, noting the company more than doubled its revenue and EBITDA since 2018. “We are proud of what has been achieved and confident Zentiva will continue to excel under GTCR’s ownership,” Allen added.

Sean Cunningham, Managing Director and Head of Healthcare at GTCR, welcomed the partnership with Zentiva’s leadership and underscored the company’s efficient manufacturing and strong product pipeline as key assets for future growth.

The deal is subject to customary regulatory approvals, with closing expected in early 2026.

Advent was advised by Goldman Sachs, PJT Partners, and Freshfields, while GTCR was supported by Barclays, BNP Paribas, Morgan Stanley, and Kirkland & Ellis.